Feanalytic’s novel diagnostic method for detecting and monitoring inflammatory bowel disease (IBD)

IBD is a severe incurable autoimmune disease. Its main subtypes are ulcerative colitis and Crohn’s disease. IBD is also a major risk factor for colorectal cancer. Today up to 8 million people have been diagnosed with IBD and its prevalence is expected to increase.

Feanalytic develops a new non-invasive diagnostic assay to detect and monitor IBD and its subtypes. The new diagnostic tool will improve IBD diagnosis and treatment planning.

Chronic abdominal symptoms are common diagnostic challenge

Various gut diseases and disorders are relatively common and occasional gut symptoms are familiar to most of the people. The severe gut diseases like IBD are sometimes difficult to diagnose because they share similar symptoms with other chronic but less harmfull conditions.

Feanalytic assay identifies IBD and its major subtypes from other gut diseases with overlapping symptoms. This offers better diagnostic tool for planning correct treatment for IBD patients.